Endovia Health Sciences, Inc.
Endovia Health Sciences, Inc. operates a beverage business focused on alcoholic products, including Chispo Tequila, and is seeking to expand into cannabinoid wellness products through a proposed acquisition of Medterra CBD, LLC. Chispo is a blue agave blanco tequila produced in Mexico under contract manufacturing arrangements. Endovia distributes the brand to one customer and has an arrangement to distribute it in certain U.S. states, Guatemala and Europe. Its products are made by third-party bottlers, co-packers and distillers, and beverage-alcohol products are distributed through independent distributors rather than sold directly to retailers. Endovia’s letter of intent with Medterra describes a potential business combination, but the parties have not entered into a definitive agreement. Medterra is a manufacturer and multi-brand operator of federally compliant cannabinoid wellness products. Endovia is a Nevada corporation headquartered in Fort Lauderdale, Florida.
No enriched coverage for $EDVA in the last 7 days.
No SEC Form 4 filings for $EDVA in the last 30 days.
See all $EDVA insider activity →Endovia Health Sciences (EDVA) expanded its equity line of credit with C/M Capital Master Fund, increasing the commitment from $35M to $135M. The addendum, effective Oct 22, 2026, updates terms for sales beyond the initial 10.875M shares, providing additional financing capacity for the company.
Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 22, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into an Addendum to that certain Securities Purchase Agreement dated September 19, 2025 providing for an equity line of credit facility
Endovia Health Sciences (EDVA) amended its equity line of credit agreement with C/M Capital Master Fund, raising the ownership cap from 4.99% to 9.99% and waiving certain provisions. The changes, effective immediately, enhance the company's access to capital.
Recent EDVA coverage spans corporate actions, regulation and earnings.
The larger equity line may support growth initiatives and improve liquidity.
The $100 M increase in financing capacity could boost liquidity and fund growth, likely supporting the stock price.
The amendment increases financing flexibility and may support future capital raises.
The amendment increases the investor’s allowable ownership under the equity line, potentially changing dilution and selling overhang dynamics.
Small private placement likely causes negligible price movement.
AlphAI scores every news story that mentions EDVA with an AI model for sentiment and relevance, and aggregates insider trades from Endovia Health Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Endovia Health Sciences (EDVA) expanded its equity line of credit with C/M Capital Master Fund, increasing the commitment from $35M to $135M. The addendum, effective Oct 22, 2026, updates terms for sales beyond the initial 10.875M shares, providing additional financing capacity for the company.
1 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 22, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into an Addendum to that certain Securities Purchase Agreement dated September 19, 2025 providing for an equity line of credit facility
1 min readEndovia Health Sciences (EDVA) amended its equity line of credit agreement with C/M Capital Master Fund, raising the ownership cap from 4.99% to 9.99% and waiving certain provisions. The changes, effective immediately, enhance the company's access to capital.
1 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 15, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into a letter agreement (the “Letter Agreement”) with C/M Capital Master Fund, LP (the “Investor”) pursuant to which parties agreed to
3 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On September 30, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 526,582 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Maste
1 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway Companies to Meet Formally with FDA’s Center for Veterinary Medicine on Novembe
2 min readEndovia Health Sciences (EDVA) received FDA minor-use status for CannEpil, a treatment for canine bone cancer pain, enabling a conditional approval pathway. The company will meet with the FDA on Nov. 19 and plans U.S. manufacturing for a potential 2027 launch, pending approvals.
1 min readEndovia Health Sciences (EDVA) and Lupvindol BioSciences announced that the FDA determined CannEpil, a CBD/THC oral solution for canine bone cancer pain, qualifies for the MUMS program, enabling a conditional approval pathway. The companies plan to meet with the FDA in November and aim for a potential 2027 commercial launch, pending regulatory approval and manufacturing readiness.
2 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 18, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into an agreement (the “Letter Agreement”) with C/M Capital Master Fund, LP (the “Investor”) pursuant to which the Investor as a coun
1 min readWorthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.
2 min read
